{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:06Z","timestamp":1791903306867,"version":"4.3.4"},"reference-count":62,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Pre-mRNA splicing gene mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) induce R-loops, which trigger ataxia telangiectasis and Rad3\u2013related kinase (ATR). We studied ceralasertib, an orally bioavailable ATR inhibitor, in adults with relapsed or refractory (R\/R) MDS or CMML in a phase 1b\/2 study 160mg twice daily during 28-day cycles on 2 dosing schedules: days 1 to 14 (14on\/14off) or days 1-7 and 15-21 (7on\/7off). Response rates and survival were estimated. Forty-four evaluable patients were treated. Grade \u22653 adverse events included thrombocytopenia (n = 13), anemia (n = 12), neutropenia (n = 9), febrile neutropenia (n = 9), pneumonia (n = 6), and hypoxia (n = 5). Thrombocytopenia requiring a platelet transfusion during the first cycle was reduced to 1 of 10 patients on 7on\/7off compared with 8\/16 patients on 14on\/14off among patients with a baseline platelet count &amp;gt;50 \u00d7 109\/L (P = .087). Overall response rate (ORR) was 29.5% (13\/44 patients) and included 1 complete response (CR), 5 marrow CR (2 with hematologic improvement [HI] in neutrophils [HI-N]), and 7 with HI (HI in erythroid\/red cells, n = 4; HI-N, n = 2; HI in platelets, n = 1). Median progression-free survival (PFS) was 4.8 months, and overall survival (OS) was 12 months. ORR (P = .72), PFS (P = .9), and OS (P = .65) did not differ between schedules. Splicing factor mutation variant allele frequencies (VAFs) remained stable while RUNX1 mutation VAFs typically increased at progression. Serum inflammatory cytokine levels (TNFRSF8 [CD30], TNF family members) decreased during ceralasertib exposure; this effect was blunted in RUNX1-mutant samples. Ceralasertib 160 mg twice daily on days 1-7 and 15-21 was established as monotherapy dosing. This trial was registered at www.clinicaltrials.gov as NCT03770429.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019848","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:03:09Z","timestamp":1782860589000},"page":"6645-6660","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A phase 1b\/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2169-4115","authenticated-orcid":false,"given":"Andrew M.","family":"Brunner","sequence":"first","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-2877","authenticated-orcid":false,"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[{"name":"4Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gutierrez Moore","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar Nonavinkere","family":"Srivatsan","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Shao","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Aubrey","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Amrein","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Narayan","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-3981","authenticated-orcid":false,"given":"Rahul","family":"Vedula","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Friedman","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Andrade-Campos","sequence":"additional","affiliation":[{"name":"6AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Smith","sequence":"additional","affiliation":[{"name":"6AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-6447","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Walter","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Graubert","sequence":"additional","affiliation":[{"name":"1Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan A.","family":"Jacoby","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026101310415135200_bib1","doi-asserted-by":"crossref","first-page":"101128","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev"},{"issue":"7","key":"2026101310415135200_bib2","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"2026101310415135200_bib3","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026101310415135200_bib4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International Scoring System for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2026101310415135200_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41408-022-00765-8","article-title":"Management of patients with lower-risk myelodysplastic syndromes","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10399","key":"2026101310415135200_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"The Lancet"},{"issue":"10423","key":"2026101310415135200_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"2026101310415135200_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2026101310415135200_bib9","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026101310415135200_bib10","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"JCO"},{"issue":"6","key":"2026101310415135200_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"2026101310415135200_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026101310415135200_bib13","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2026101310415135200_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat Genet"},{"issue":"15","key":"2026101310415135200_bib15","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2026101310415135200_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"15","key":"2026101310415135200_bib17","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2026101310415135200_bib18","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2026101310415135200_bib19","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"key":"2026101310415135200_bib20","doi-asserted-by":"crossref","first-page":"107390","DOI":"10.1016\/j.leukres.2023.107390","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"134","author":"Haque","year":"2023","journal-title":"Leuk Res"},{"key":"2026101310415135200_bib21","doi-asserted-by":"crossref","first-page":"20406207241275376","DOI":"10.1177\/20406207241275376","article-title":"Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","volume":"15","author":"Watts","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2026101310415135200_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol Cell"},{"issue":"3","key":"2026101310415135200_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molcel.2019.01.024","article-title":"R-loops as cellular regulators and genomic threats","volume":"73","author":"Crossley","year":"2019","journal-title":"Mol Cell"},{"issue":"18","key":"2026101310415135200_bib24","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","article-title":"Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"2026101310415135200_bib25","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","article-title":"SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications","volume":"34","author":"Singh","year":"2020","journal-title":"Leukemia"},{"issue":"22","key":"2026101310415135200_bib26","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J Med Chem"},{"issue":"11","key":"2026101310415135200_bib27","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3324\/haematol.2020.254193","article-title":"Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations","volume":"106","author":"Flach","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2026101310415135200_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"2026101310415135200_bib29","first-page":"16","article-title":"PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"issue":"17","key":"2026101310415135200_bib30","first-page":"2047","article-title":"Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026101310415135200_bib31","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"2026101310415135200_bib32","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1303.3997","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","author":"Li","year":"26  2013","journal-title":"arXiv"},{"issue":"3","key":"2026101310415135200_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmoldx.2021.10.013","article-title":"Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence","volume":"24","author":"Miller","year":"2022","journal-title":"J Mol Diagn"},{"issue":"3","key":"2026101310415135200_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2026101310415135200_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"issue":"3","key":"2026101310415135200_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"issue":"11","key":"2026101310415135200_bib37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/bloodadvances.2017014183","article-title":"A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion","volume":"2","author":"Miller","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2026101310415135200_bib38","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"Plos Comput Biol"},{"issue":"7","key":"2026101310415135200_bib39","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"2026101310415135200_bib40","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2026101310415135200_bib41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2026101310415135200_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2026101310415135200_bib43","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3324\/haematol.2012.071050","article-title":"Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure","volume":"98","author":"Pr\u00e9bet","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2026101310415135200_bib44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2026101310415135200_bib45","doi-asserted-by":"crossref","first-page":"e165615","DOI":"10.1172\/jci.insight.165615","article-title":"The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy","volume":"8","author":"Vendetti","year":"2023","journal-title":"JCI Insight"},{"issue":"13 suppl","key":"2026101310415135200_bib46","article-title":"Abstract CT026: phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers","volume":"78","author":"Krebs","year":"2018","journal-title":"Cancer Res"},{"issue":"17","key":"2026101310415135200_bib47","doi-asserted-by":"crossref","first-page":"e152673","DOI":"10.1172\/JCI152673","article-title":"Bone marrow\u2013confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia","volume":"132","author":"Mei","year":"2022","journal-title":"J Clin Invest"},{"issue":"8","key":"2026101310415135200_bib48","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-017-3036-4","article-title":"Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes","volume":"96","author":"Bestach","year":"2017","journal-title":"Ann Hematol"},{"issue":"9","key":"2026101310415135200_bib49","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026101310415135200_bib50","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1038\/s41467-024-50925-6","article-title":"Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"issue":"43","key":"2026101310415135200_bib51","doi-asserted-by":"crossref","first-page":"eabo5840","DOI":"10.1126\/sciadv.abo5840","article-title":"ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus","volume":"8","author":"Manolakou","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"2026101310415135200_bib52","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026101310415135200_bib53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/procel\/pwae059","article-title":"JMJD1C forms condensate to facilitate a RUNX1-dependent gene expression program shared by multiple types of AML cells","volume":"16","author":"Chen","year":"2025","journal-title":"Protein Cell"},{"issue":"5","key":"2026101310415135200_bib54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4049\/jimmunol.2100917","article-title":"CRISPR activation screening identifies VGLL3-TEAD1-RUNX1\/3 as a transcriptional complex for PD-L1 expression","volume":"209","author":"Wijdeven","year":"2022","journal-title":"J Immunol"},{"issue":"11","key":"2026101310415135200_bib55","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1800672","article-title":"Runx1 and ROR\u03b3t cooperate to upregulate IL-22 expression in Th cells through its distal enhancer","volume":"202","author":"Sekimata","year":"2019","journal-title":"J Immunol"},{"issue":"11","key":"2026101310415135200_bib56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ni.1663","article-title":"Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells","volume":"9","author":"Zhang","year":"2008","journal-title":"Nat Immunol"},{"issue":"4","key":"2026101310415135200_bib57","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2007-06-093682","article-title":"p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death","volume":"111","author":"Krejci","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2026101310415135200_bib58","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2026101310415135200_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2024025670","article-title":"Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem\/progenitor cells","volume":"146","author":"Takashima","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026101310415135200_bib60","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood.2021014418","article-title":"Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"139","author":"Weeks","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026101310415135200_bib61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000699","article-title":"The significance of CUX1 and chromosome 7 in myeloid malignancies","volume":"29","author":"Jotte","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2026101310415135200_bib62","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/0008-5472.CAN-23-3239","article-title":"R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6645\/2592427\/blooda_adv-2026-019848-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6645\/2592427\/blooda_adv-2026-019848-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:42:02Z","timestamp":1791902522000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6645\/569439\/A-phase-1b-2-study-of-ceralasertib-a-selective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":62,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019848","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,29]]}}}